Literature DB >> 17394548

Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1.

Elisa Greggio1, Patrick A Lewis, Marcel P van der Brug, Rili Ahmad, Alice Kaganovich, Jinhui Ding, Alexandra Beilina, Acacia K Baker, Mark R Cookson.   

Abstract

Several mutations have been found in the leucine-rich repeat kinase 2 gene (LRRK2), encoding the protein dardarin, which are associated with autosomal dominant Parkinson disease. We have previously shown that mutant LRRK2/dardarin is toxic to neurons and neuron-like cell lines in culture and that some mutations are also associated with an inclusion-body phenotype. There is a homologous kinase, LRRK1, which has a similar domain structure but is not known to carry mutations causing Parkinson disease. In the current study, we introduced mutations at equivalent residues in both LRRK2 and LRRK1 to determine their effects in cells. We show that mutations in dardarin are more prone to form inclusion bodies in transfected cells and are more toxic than equivalent mutations in LRRK1. This work suggests that dardarin/LRRK2 is inherently more damaging than LRRK1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17394548     DOI: 10.1111/j.1471-4159.2007.04523.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  46 in total

1.  LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins.

Authors:  C H Hsu; D Chan; B Wolozin
Journal:  Neurodegener Dis       Date:  2010-02-18       Impact factor: 2.977

Review 2.  Evolution of neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Biol       Date:  2012-09-11       Impact factor: 10.834

Review 3.  Receptor-interacting protein (RIP) kinase family.

Authors:  Duanwu Zhang; Juan Lin; Jiahuai Han
Journal:  Cell Mol Immunol       Date:  2010-04-12       Impact factor: 11.530

4.  Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease.

Authors:  Justus C Dachsel; Kenya Nishioka; Carles Vilariño-Güell; Sarah J Lincoln; Alexandra I Soto-Ortolaza; Jennifer Kachergus; Kelly M Hinkle; Michael G Heckman; Barbara Jasinska-Myga; Julie P Taylor; Dennis W Dickson; Rachel A Gibson; Faycal Hentati; Owen A Ross; Matthew J Farrer
Journal:  Mech Ageing Dev       Date:  2010-02-06       Impact factor: 5.432

5.  LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans.

Authors:  Shamol Saha; Maria D Guillily; Andrew Ferree; Joel Lanceta; Diane Chan; Joy Ghosh; Cindy H Hsu; Lilach Segal; Kesav Raghavan; Kunihiro Matsumoto; Naoki Hisamoto; Tomoki Kuwahara; Takeshi Iwatsubo; Landon Moore; Lee Goldstein; Mark Cookson; Benjamin Wolozin
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

6.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

7.  Intramolecular activation mechanism of the Dictyostelium LRRK2 homolog Roco protein GbpC.

Authors:  Wouter N van Egmond; Arjan Kortholt; Katarzyna Plak; Leonard Bosgraaf; Sylvia Bosgraaf; Ineke Keizer-Gunnink; Peter J M van Haastert
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

Review 8.  It takes two to tango: regulation of G proteins by dimerization.

Authors:  Raphael Gasper; Simon Meyer; Katja Gotthardt; Minhajuddin Sirajuddin; Alfred Wittinghofer
Journal:  Nat Rev Mol Cell Biol       Date:  2009-05-08       Impact factor: 94.444

9.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

10.  The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation.

Authors:  Azad Kumar; Elisa Greggio; Alexandra Beilina; Alice Kaganovich; Diane Chan; Jean-Marc Taymans; Benjamin Wolozin; Mark R Cookson
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.